Sanguine BioSciences Closes Seed Funding Round | GenomeWeb

NEW YORK (GenomeWeb News) – Biospecimen firm Sanguine BioSciences announced on Thursday the closing of its seed funding round.

The round was led by Invent Ventures and Heliant Ventures and will be used to further build Sanguine's infrastructure, it said. Sanguine did not disclose the amount of the funding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.